Biocrates Life Sciences Ag

Infandx Ag

Metabolomycs, Inc

Idcgs Clinica De Diagnosticos Medicos

Centro De Genomas

Idcgs Clínica De Diagnósticos Médicos Ltda

Fundação Pio Xii - Hospital De Câncer De Barretos

Therese Koal

Ismael Dale Cotrim Guerreiro Da Silva

Hans-Peter Deigner

David Enot

Matthias Keller

Ronnaug Solberg

Edson Guimaraes Lo Turco

Edson Guimaraes Loturco

Ricoardo Soubie Diaz

Andre Lopes Carvalho

Matthias Kohl

Rene Aloisio Da Costa Vieira

Olga Saugstad

Ola Didrik Saugstad

René Aloisio Da Costa Vieira

Klaus Weinberger

Rønnaug Solberg

The present invention relates to a metabolic biomarker set for use in assessing breast cancer in a mammalian subject. In particular, the invention relates to a metabolic biomarker set for screening and/or diagnosing breast cancer, the metabolic biomarker set including at least (a) one amino acid selected from glutamine, glutamate and serine, and one lipid, or (b) glutamine and glutamate. Further, the invention relates to a metabolic biomarker set for prediction of therapeutic response to breast cancer neoadjuvant chemotherapy. Moreover, the present invention relates to a method for assessing breast cancer, which includes obtaining a biological sample, preferably blood, from a mammalian subject and measuring in the biological sample the amount and/or ratios of metabolites. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess breast cancer.

Biomarkers for assessing breast cancer

A method for in vitro diagnosing asphyxia and disorders related thereto, a method of in vitro estimating duration of hypoxia in a patient subjected to asphyxia, and a method for in vitro monitoring of normoxic, hypoxic and hyperoxic conditions and/or normobaric and hyperbaric oxygen therapy, includes quantitatively detecting in a biological sample of a patient a plurality of asphyxia specific endogenous compounds which are selected from the group consisting of biogenic amines; carnitine-derived compounds; amino acids; bile acids; carboxylic acids; eicosanoids; lipids; precursors of cholesterol, cholesterol metabolites; prostanoids; and sugars.

Method of diagnosing and treating asphyxia

A metabolic biomarker set for use in assessing, screening, and/or diagnosing breast cancer in a mammalian subject includes at least (a) one amino acid selected from glutamine, glutamate and serine, and one lipid, or (b) glutamine and glutamate. Described further, is a metabolic biomarker set for prediction of therapeutic response to breast cancer neoadjuvant chemotherapy; a metabolic biomarker set for assessing biochemical reflection of breast cancer tumor activity; and a metabolic biomarker set for subclassification between intrinsic breast cancer tumor subtypes. Moreover, a method for assessing breast cancer is described, which includes obtaining a biological sample, preferably blood, from a mammalian subject and measuring in the biological sample the amount and/or ratios of metabolites. By employing the specific biomarkers and the method it becomes possible to more properly and reliably assess breast cancer.

The present invention relates to metabolic biomarker sets for assessing HIV. In preferred embodiments, the present invention relates to the use of biomarker sets for screening and/or diagnosing HIV infection, for prediction of immunologic response of a mammalian subject to antiretroviral therapy and/or prognosis of HIV disease progression, and for monitoring of HIV disease activity in a mammalian subject. In other embodiments, the invention relates to methods for screening and/or diagnosing HIV infection, for prediction of immunologic response of a mammalian subject to antiretroviral therapy and/or prognosis of HIV disease progression, and for monitoring of HIV disease activity in a mammalian subject, as well as to a kit adapted to carry out the methods. By employing the specific biomarkers and the method according to the present invention it becomes possible to more properly and reliably assess HIV. In particular, it becomes possible to screen for and diagnose HIV in a patient with high accuracy and predict early in advance the patient's therapeutic response to antiretroviral therapy.

Biomarkers for assessing HIV

Growing community of inventors

Innsbruck, Austria

Therese Koal